Cover Image
Market Research Report - 247615

Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers

Published by GlobalData
Published Content info 81 Pages
Price
Back to Top
Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers
Published: July 24, 2012 Content info: 81 Pages
Description

Summary

GlobalData's "Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers" Report integrates deep research of top players in the pharmaceutical industry with our proprietary analysis and ranking methodology to reveal top performers, industry trends, and the strategies that successful companies are using to stay ahead in the increasingly demanding pharmaceutical marketplace. Clients can use this report for strategic planning and tracking of competitor strategies. The report covers major drug approvals and significant M&A and license agreements, as well as other significant cost-containment and operations strategies.

Scope

  • Full financial details and for the top 25 pharmaceutical companies including detailed analysis of key performance metrics.
  • Analysis of the key drivers, trends, and strategies employed by leading companies across important geographic regions including the US, EU, Japan, Asia-Pacific, Brazil, Russia, India, China, and other emerging markets.
  • In addition to the six major therapy areas of cardiovascular disease, central nervous system (CNS), diabetes and metabolic, immunology, oncology, and respiratory diseases, the report analyzes the leading players in the generic pharmaceuticals market.
  • The report includes analysis of important events in 2010 and 2011 that drove the success of leading companies during the year.

Reasons to buy

  • Analyze and emulate the strategies that successful companies are using to maintain their lead in the increasingly competitive global pharmaceutical market.
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, even if they are not revenue leaders.
  • Identify the important disease areas, types of products, and geographical areas where successful companies are expanding to ensure their future success.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Upcoming Related Reports

3. Industry Dynamics

  • 3.1. The 'Patent Cliff' Will Erode Earnings Over the Next Three Years
  • 3.2. The Number of Deals and Deal Values Declined in 2011
    • 3.2.1. Sanofi Makes Move into Rare Diseases with Genzyme Acquisition
    • 3.2.2. Novartis 'Sees' Alcon as an Opportunity for U.S. Growth
    • 3.2.3. Teva to Focus on Branded Drugs with its Acquisition of Cephalon
    • 3.2.4. Watson Looks for a Foothold in Emerging Europe with Actavis Purchase
  • 3.3. Thirty-Five New Innovative Drugs Approved by the FDA in 2011

4. GlobalData Benchmark Rankings

5. Financial Performance

  • 5.1. Revenue Leaders
    • 5.1.1. Pfizer
    • 5.1.2. Johnson &Johnson
    • 5.1.3. Novartis
  • 5.2. Revenue Laggards
    • 5.2.1. Watson
    • 5.2.2. Celgene
    • 5.2.3. Biogen Idec
  • 5.3. Revenue Growth Leaders
    • 5.3.1. Celgene
    • 5.3.2. Watson Pharmaceuticals
    • 5.3.3. Novartis
  • 5.4. Revenue Growth Laggards
    • 5.4.1. Pfizer
    • 5.4.2. AstraZeneca
    • 5.4.3. GlaxoSmithKline
  • 5.5. Gross Margin Leaders
    • 5.5.1. Celgene
    • 5.5.2. Biogen Idec
    • 5.5.3. Allergan
  • 5.6. Gross Margin Laggards
    • 5.6.1. Mylan
    • 5.6.2. Watson
    • 5.6.3. Bayer
  • 5.7. Operating Margin Leaders
    • 5.7.1. Gilead
    • 5.7.2. AstraZeneca
    • 5.7.3. Biogen Idec
  • 5.8. Operating Margin Laggards
    • 5.8.1. Astellas
    • 5.8.2. Bayer
    • 5.8.3. Daiichi Sankyo

6. Expense Performance

  • 6.1. R&D Spending Leaders
    • 6.1.1. Mylan, Teva, and Watson
    • 6.1.2. Novo Nordisk
    • 6.1.3. Bayer
  • 6.2. R&D Spending Laggards
    • 6.2.1. Celgene
    • 6.2.2. Biogen Idec
    • 6.2.3. Astellas
  • 6.3. SG&A Spending Leaders
    • 6.3.1. Gilead
    • 6.3.2. Watson
    • 6.3.3. Mylan
  • 6.4. SG&A Spending Laggards
    • 6.4.1. Eisai
    • 6.4.2. Allergan
    • 6.4.3. Novo Nordisk

7. Regional Performance

  • 7.1. United States
    • 7.1.1. Watson
    • 7.1.2. Celgene
    • 7.1.3. Mylan
  • 7.2. Europe
    • 7.2.1. Teva
    • 7.2.2. Celgene
    • 7.2.3. Watson
    • 7.2.4. Allergan
  • 7.3. Asia Pacific
    • 7.3.1. Eli Lilly
    • 7.3.2. Sanofi
    • 7.3.3. Biogen Idec
    • 7.3.4. Novartis
  • 7.4. Japan
    • 7.4.1. Sanofi
    • 7.4.2. Eli Lilly
    • 7.4.3. Merck & Co.
  • 7.5. BRIC and Emerging Markets
    • 7.5.1. Teva
    • 7.5.2. Abbott
    • 7.5.3. Novartis

8. Therapy Franchise Analysis

  • 8.1. Cardiovascular
    • 8.1.1. Pfizer
    • 8.1.2. AstraZeneca
    • 8.1.3. Sanofi
    • 8.1.4. Takeda
  • 8.2. Oncology
    • 8.2.1. Roche
    • 8.2.2. Novartis
    • 8.2.3. Celgene
  • 8.3. Central Nervous System
    • 8.3.1. Eli Lilly
    • 8.3.2. Pfizer
    • 8.3.3. AstraZeneca
    • 8.3.4. Teva
  • 8.4. Respiratory
    • 8.4.1. GSK
    • 8.4.2. Merck& Co.
    • 8.4.3. AstraZeneca
    • 8.4.4. Boehringer Ingelheim
  • 8.5. Immunology
    • 8.5.1. Abbott
    • 8.5.2. Pfizer
    • 8.5.3. J&J
  • 8.6. Diabetes
    • 8.6.1. Novo Nordisk
    • 8.6.2. Sanofi
    • 8.6.3. Merck & Co.

9. Generic Drug Maker Analysis

  • 9.1. Teva
  • 9.2. Novartis Sandoz
  • 9.3. Mylan
  • 9.4. Watson

10. GlobalData Case Study:Makena from KV Pharmaceutical

11. End of Report

12. Appendix

  • 12.1. Tables and Figures
  • 12.2. Methodology
    • 12.2.1. Coverage
    • 12.2.2. Secondary Research
    • 12.2.3. Expert Panel Validation
  • 12.3. About the Author
  • 12.4. About GlobalData
  • 12.5. Contact Us
  • 12.6. Disclaimer

List of Tables

  • Table 1: Recent and Upcoming US Patent Expirations with FY2010 and FY2011 Sales Data
  • Table 2: GlobalData Rankings, FY2009-FY2011
  • Table 3: FY2011 Top 3 Revenue Leaders
  • Table 4: FY2011 Top 3 Revenue Laggards
  • Table 5: FY2011 Top 3 Revenue Growth Leaders
  • Table 6: FY2011 Top 3 Revenue Growth Laggards
  • Table 7: FY2011 Top 3 Gross Margin Leaders
  • Table 8: FY2011 Top 3 Gross Margin Laggards
  • Table 9: FY2011 Top 3 Operating Margin Leaders
  • Table 10: FY2011 Top 3 Operating Margin Laggards
  • Table 11: FY2011 Top R&D Spend Leaders as a Percentage of Revenue
  • Table 12: FY2011 Top 3 R&D Spend Laggards as a Percentage of Revenue
  • Table 13: FY2011 Top 3 SG&A Spend Leaders as a Percentage of Revenue
  • Table 14: FY2011 Top 3 SG&A Spend Laggards as a Percentage of Revenue
  • Table 15: FY2011 Top 3 US Region Revenue Growth Leaders
  • Table 16: FY2011 Top EU Region Revenue Growth Leaders
  • Table 17: FY2011 Top APAC Revenue Growth Leaders
  • Table 18: FY2011 Top 3 Japan Region Revenue Growth Leaders
  • Table 19: FY2011 Top 3 BRIC and Emerging Revenue Growth Leaders
  • Table 20: FY2011 Top 3 Cardiovascular Franchise Revenue Leaders
  • Table 21: FY2011 Top 3 Oncology Franchise Revenue Leaders
  • Table 22: FY2011 Top 3 CNS Franchise Revenue Leaders
  • Table 23: FY2011 Top 3 Respiratory Franchise Revenue Leaders
  • Table 24: FY2011 Top 3 Immunology Franchise Revenue Leaders
  • Table 25: FY2011 Top 3 Diabetes Franchise Revenue Leaders
  • Table 26: FY2011 Top 3 Generic Drug Manufacturers

List of Figures

  • Figure 1: Deal Analysis -Total Number of Deals and Deal Values ($m), FY2007-FY2011
  • Figure 2: Deal Analysis - Number of M&A Deals and Deal Values ($m), FY2007-FY2011
  • Figure 3: Deal Analysis - Deal Type as a Percentage of Total Deals for FY2011
  • Figure 4: Number of FDA Approvals - NMEs Approved, from FY2007-FY2011
  • Figure 5: Top 25 Pharmaceutical Landscape Assessment - FY2011 Revenue Growth vs. Operating Margin
  • Figure 6: FY2011 Leading Pharmaceutical Companies by Revenue ($m)
  • Figure 7: FY2011 Leading Pharmaceutical Companies by Year-to-Year Revenue Growth
  • Figure 8: FY2011 Leading Pharmaceutical Companies by Gross Margin
  • Figure 9: FY2011 Leading Pharmaceutical Companies by Operating Margin
  • Figure 10: Top 25 Pharmaceutical Landscape Assessment - FY2011 S,G&A Spend vs. R&D Spend
  • Figure 11: Leading Pharmaceutical Companies by R&D Spend as a Percentage of Revenue
  • Figure 12: Leading Pharmaceutical Companies by SG&A Spend as a Percentage of Revenue
  • Figure 13: US Region Landscape Assessment - FY2011 US Revenue Growth vs. Corporate Revenue Growth
  • Figure 14: FY2011US Region Year-to-Year Revenue Growth
  • Figure 15: EU Region Landscape Assessment - FY2011 EU Revenue Growth vs. Corporate Revenue Growth
  • Figure 16: FY2011 EU Region Year-to-Year Revenue Growth
  • Figure 17: APAC Region Landscape Assessment - FY2011 APAC Revenue Growth vs. Corporate Revenue Growth
  • Figure 18: FY2011 APAC Region Year-to-Year Revenue Growth
  • Figure 19: Japan Region Landscape Assessment - FY2011 Japan Revenue Growth vs. Corporate Revenue Growth
  • Figure 20: FY2011 Japan Region Year-to-Year Revenue Growth
  • Figure 21: BRIC and Emerging Markets Region Landscape Assessment - FY2011 BRIC/Emerging Revenue Growth vs. Corporate Revenue Growth
  • Figure 22: FY2011 BRIC and Emerging Region Year-to-Year Revenue Growth
  • Figure 23: FY2011 vs. FY2010 Therapy Franchise Sales ($m)
  • Figure 24: FY2011 Cardiovascular Franchise Sales ($m)
  • Figure 25: FY2011 Oncology Franchise Sales ($m)
  • Figure 26: FY2011 CNS Franchise Sales ($m)
  • Figure 27: FY2011 Respiratory Franchise Sales ($m)
  • Figure 28: FY2011 Immunology Franchise Sales ($m)
  • Figure 29: FY2011 Diabetes Franchise Sales ($m)
  • Figure 30: FY2011 Leading Generic Drug Makers by Sales ($m)
  • Figure 31: Top 25 Pharmaceutical Landscape Assessment - FY2011 Revenue Growth vs. OperatingMargin
  • Figure 32: FY2011 Leading Pharmaceutical Companies by Revenue ($m)
  • Figure 33: FY2011 Leading Pharmaceutical Companies by R&D Spending FY2011 vs. FY2010 ($m)
  • Figure 34: Japan Region Landscape Assessment - FY2011 Japan Revenue Growth vs. Corporate Revenue Growth
  • Figure 35: Number of Deals, by Type, FY2007-FY2011
Back to Top